^
    Back
    Association details:
    Biomarker:CD20 positive
    Cancer:Chronic Lymphocytic Leukemia
    Drug:Ruxience (rituximab-pvvr) (CD20 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    Therapeutic Goods Administration
    Published date:
    03/10/2021
    Excerpt:
    Australian prescription medicine decision summary...Ruxience (rituximab) was approved for the following therapeutic use...Chronic lymphocytic leukaemia...Ruxience is indicated for the treatment of patients with CD20 positive chronic lymphocytic leukaemia (CLL) in combination with chemotherapy.
    Secondary therapy:
    Chemotherapy
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    05/26/2020
    Excerpt:
    RUXIENCE (rituximab-pvvr) is a CD20-directed cytolytic antibody indicated for the treatment of adult patients with...Chronic Lymphocytic Leukemia (CLL)...Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC).
    Secondary therapy:
    FC
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    European Medicines Agency
    Published date:
    04/07/2020
    Excerpt:
    Ruxience is a medicine used in adults to treat the following blood cancers and inflammatory conditions....chronic lymphocytic leukaemia (CLL, another blood cancer affecting white blood cells)